GGrantIndex
← Leaderboards

Dorothee M Herlyn

Wistar Institute

Google Scholar ↗PubMed ↗ORCID ↗
$8,362,969
Attributed
$8,362,969
Total exposure
11
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $940.6K · FY2005–12
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12

Funding mix

By agency

NIH$12,242,131 · 12

By mechanism

P01$7,997,359 · 6
R01$1,653,430 · 2
P50$1,469,509 · 2
R33$981,625 · 1
R21$140,208 · 1

Top collaborators

No co-investigators on record.

Others in their field

Top investigators on “Tumor Antigens”

Research focus

Tumor AntigensMelanomaNeoplasm /Cancer ImmunotherapyCytotoxic T LymphocyteHuman SubjectColorectal NeoplasmsCellular ImmunityClinical ResearchNeoplastic CellHelper T LymphocyteBaseTumorT-LymphocyteVaccinesImmunotherapyLymphocyteHumoral ImmunityImmune ResponseNeoplasm /Cancer ImmunologyBinding (Molecular Function)CytotoxicImmunizationGenerationsGrowth

Grant awards (38)

Mutant BRAF as a Therapeutic Target for Melanoma$366,128
P01 · FY2012 · CA · contact PI
Mutant BRAF as a Therapeutic Target for Melanoma$360,960
P01 · FY2011 · CA · contact PI
Mutant BRAF as a Therapeutic Target for Melanoma$390,723
P01 · FY2010 · CA · contact PI
Mutant BRAF as a Therapeutic Target for Melanoma$407,790
P01 · FY2009 · CA · contact PI
Breaking tolerance to mEGP self-antigen$239,213
R01 · FY2009 · CA · contact PI
CTL-based Immunotherapy in an Organotypic Melanoma Culture System$441,335
P50 · FY2008 · CA · contact PI
Mutant BRAF as a Therapeutic Target for Melanoma$301,758
P01 · FY2008 · CA · contact PI
Breaking tolerance to mEGP self-antigen$197,513
R01 · FY2008 · CA · contact PI
CTL-based Immunotherapy in an Organotypic Melanoma Culture System$445,471
P50 · FY2007 · CA · contact PI
Breaking tolerance to mEGP self-antigen$222,519
R01 · FY2007 · CA · contact PI
CTL-based Immunotherapy in an Organotypic Me$264,435
P50 · FY2006 · CA · contact PI
Breaking tolerance to mEGP self-antigen$226,217
R01 · FY2006 · CA · contact PI
EGF-RvIII in Breast Cancer$259,067
R01 · FY2005 · CA
CTL-based Immunotherapy in an Organotypic Me$159,134
P50 · FY2005 · CA
EGF-RvIII in Breast Cancer$255,949
R01 · FY2004 · CA
CTL-based Immunotherapy in an Organotypic Me$159,134
P50 · FY2004 · CA
MOLECULAR CLONING OF HLA CLASS II TUMOR ANTIGENS$317,959
R33 · FY2003 · CA
EGF-RvIII in Breast Cancer$252,952
R01 · FY2003 · CA
CO17 1A/GA733 ANTIGEN IN COLORECTAL CANCER THERAPY$1,320,582
P01 · FY2002 · CA
Melanoma antigens recognized by B and T helper lymphocytes$312,755
P01 · FY2002 · CA
Melanoma antigens recognized by B and T helper lymphocytes$312,755
P01 · FY2002 · CA
MOLECULAR CLONING OF HLA CLASS II TUMOR ANTIGENS$309,233
R33 · FY2002 · CA
PATIENTS'IMMUNE RESPONSES$228,401
P01 · FY2002 · CA
CORE--IMMUNOLOGY$228,401
P01 · FY2002 · CA
CORE--GENOMICS AND PROTEOMIC RESOURCES$0
P50 · FY2002 · CA
T CELL BASED IMMUNOTHERAPY IN A MELANOMA CULTURE SYSTEM$0
P50 · FY2002 · CA
GD2 MIMICRY BY ANTI-IDIOTYPES$0
P01 · FY2002 · CA
CO17 1A/GA733 ANTIGEN IN COLORECTAL CANCER THERAPY$1,296,031
P01 · FY2001 · CA
MOLECULAR CLONING OF HLA CLASS II TUMOR ANTIGENS$354,433
R33 · FY2001 · CA
Melanoma antigens recognized by B and T helper lymphocytes$312,755
P01 · FY2001 · CA
CORE--IMMUNOLOGY$228,401
P01 · FY2001 · CA
PATIENTS'IMMUNE RESPONSES$228,401
P01 · FY2001 · CA
T CELL BASED IMMUNOTHERAPY IN A MELANOMA CULTURE SYSTEM$0
P50 · FY2001 · CA
CO17 1A/GA733 ANTIGEN IN COLORECTAL CANCER THERAPY$1,262,549
P01 · FY2000 · CA
CORE--IMMUNOLOGY$154,053
P01 · FY2000 · CA
PATIENTS'IMMUNE RESPONSES$154,053
P01 · FY2000 · CA
MOLECULAR CLONING OF HLA CLASS II TUMOR ANTIGENS$140,208
R21 · FY2000 · CA
Melanoma antigens recognized by B and T helper lymphocytes$130,863
P01 · FY2000 · CA